AGIOS PHARMACEUTICALS, INC. Financing Cash Flow
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Financing Cash Flow of $5.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.15M, a 4744.62% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.08M, a 28.35% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.56M, a 47.19% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.43M, a 68.18% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $8.68M, a 39.93% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $14.44M, a 165.82% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $5.43M, a 131.19% increase from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $2.35M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $5.23M 10-Q · filed 2026-07-30 | $7.78M derived: sum of 3 quarters · filed 2026-07-30 | $12.22M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $2.08M 10-Q · filed 2026-04-29 | $4.63M derived: sum of 2 quarters · filed 2026-04-29 | $9.07M derived: sum of 3 quarters · filed 2026-04-29 | $9.13M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $6.99M derived: sum of 2 quarters · filed 2026-02-12 | $7.06M derived: sum of 3 quarters · filed 2026-07-30 | $8.68M 10-K · filed 2026-02-12 |
| 2025-09-30 | $4.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $4.50M derived: sum of 2 quarters · filed 2026-07-30 | $6.12M 10-Q · filed 2025-10-30 | $10.96M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.68M 10-Q · filed 2026-07-30 | $6.53M derived: sum of 3 quarters · filed 2026-07-30 | $9.16M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.62M 10-Q · filed 2026-04-29 | $6.46M derived: sum of 2 quarters · filed 2026-04-29 | $9.10M derived: sum of 3 quarters · filed 2026-04-29 | $10.20M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $7.48M derived: sum of 2 quarters · filed 2026-02-12 | $8.58M derived: sum of 3 quarters · filed 2026-02-12 | $14.44M 10-K · filed 2026-02-12 |
| 2024-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.74M derived: sum of 2 quarters · filed 2025-10-30 | $9.60M 10-Q · filed 2025-10-30 | $10.45M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $6.96M 10-Q · filed 2025-07-31 | $7.81M derived: sum of 3 quarters · filed 2026-02-12 | $9.69M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $5.86M 10-Q · filed 2025-05-01 | $6.71M derived: sum of 2 quarters · filed 2026-02-12 | $8.59M derived: sum of 3 quarters · filed 2026-02-12 | $8.83M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $847.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $2.73M derived: sum of 2 quarters · filed 2026-02-12 | $2.97M derived: sum of 3 quarters · filed 2026-02-12 | $5.43M 10-K · filed 2026-02-12 |
| 2023-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.12M derived: sum of 2 quarters · filed 2024-10-31 | $4.59M 10-Q · filed 2024-10-31 | $4.61M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $237.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.70M 10-Q · filed 2024-08-01 | $2.73M derived: sum of 3 quarters · filed 2025-02-13 | $3.91M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $2.47M 10-Q · filed 2024-05-02 | $2.49M derived: sum of 2 quarters · filed 2025-02-13 | $3.68M derived: sum of 3 quarters · filed 2025-02-13 | $3.61M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $1.21M derived: sum of 2 quarters · filed 2025-02-13 | $1.14M derived: sum of 3 quarters · filed 2025-02-13 | $2.35M 10-K · filed 2025-02-13 |
| 2022-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.12M derived: sum of 2 quarters · filed 2023-11-02 | $2.33M 10-Q · filed 2023-11-02 | -$16.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.14M 10-Q · filed 2023-08-03 | -$17.45M derived: sum of 3 quarters · filed 2024-02-15 | -$268.43M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $1.21M 10-Q · filed 2023-05-04 | -$17.38M derived: sum of 2 quarters · filed 2024-02-15 | -$268.36M derived: sum of 3 quarters · filed 2024-02-15 | -$771.82M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$18.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$269.57M derived: sum of 2 quarters · filed 2024-02-15 | -$773.03M derived: sum of 3 quarters · filed 2024-02-15 | -$765.77M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$250.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$754.44M derived: sum of 2 quarters · filed 2022-11-03 | -$747.18M 10-Q · filed 2022-11-03 | -$746.60M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$503.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$496.20M 10-Q · filed 2022-08-04 | -$495.62M derived: sum of 3 quarters · filed 2023-02-23 | -$492.17M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $7.26M 10-Q · filed 2022-05-05 | $7.84M derived: sum of 2 quarters · filed 2023-02-23 | $11.29M derived: sum of 3 quarters · filed 2023-02-23 | $263.39M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.03M derived: sum of 2 quarters · filed 2023-02-23 | $256.13M derived: sum of 3 quarters · filed 2023-02-23 | $261.52M 10-K · filed 2023-02-23 |
| 2020-09-30 | $3.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $255.55M derived: sum of 2 quarters · filed 2021-11-03 | $260.94M 10-Q · filed 2021-11-03 | $538.54M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $252.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $257.49M 10-Q · filed 2021-07-29 | $535.09M derived: sum of 3 quarters · filed 2022-02-24 | $538.43M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $5.38M 10-Q · filed 2021-04-29 | $282.99M derived: sum of 2 quarters · filed 2022-02-24 | $286.33M derived: sum of 3 quarters · filed 2022-02-24 | $290.14M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $277.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $280.94M derived: sum of 2 quarters · filed 2022-02-24 | $284.75M derived: sum of 3 quarters · filed 2022-02-24 | $289.61M 10-K · filed 2022-02-24 |
| 2019-09-30 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $7.14M derived: sum of 2 quarters · filed 2020-11-05 | $12.01M 10-Q · filed 2020-11-05 | $13.02M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $8.67M 10-Q · filed 2020-07-30 | $9.68M derived: sum of 3 quarters · filed 2021-02-25 | $16.91M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $4.86M 10-Q · filed 2020-04-30 | $5.88M derived: sum of 2 quarters · filed 2021-02-25 | $13.10M derived: sum of 3 quarters · filed 2021-02-25 | $22.61M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.24M derived: sum of 2 quarters · filed 2021-02-25 | $17.75M derived: sum of 3 quarters · filed 2021-02-25 | $546.02M 10-K · filed 2021-02-25 |
| 2018-09-30 | $7.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $16.73M derived: sum of 2 quarters · filed 2019-10-31 | $545.01M 10-Q · filed 2019-10-31 | $547.60M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $9.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $537.78M 10-Q · filed 2019-08-01 | $540.37M derived: sum of 3 quarters · filed 2020-02-19 | $545.70M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $528.28M 10-Q · filed 2019-05-02 | $530.87M derived: sum of 2 quarters · filed 2020-02-19 | $536.19M derived: sum of 3 quarters · filed 2020-02-19 | $809.34M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $7.91M derived: sum of 2 quarters · filed 2020-02-19 | $281.06M derived: sum of 3 quarters · filed 2020-02-19 | $285.11M 10-K · filed 2020-02-19 |
| 2017-09-30 | $5.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $278.48M derived: sum of 2 quarters · filed 2018-11-01 | $282.52M 10-Q · filed 2018-11-01 | $286.51M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | $273.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $277.20M 10-Q · filed 2018-08-02 | $281.19M derived: sum of 3 quarters · filed 2019-02-14 | $444.42M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $4.05M 10-Q · filed 2018-05-04 | $8.04M derived: sum of 2 quarters · filed 2019-02-14 | $171.27M derived: sum of 3 quarters · filed 2019-02-14 | |
| 2016-12-31 | $3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $167.22M derived: sum of 2 quarters · filed 2019-02-14 | $169.78M 10-K · filed 2019-02-14 | |
| 2016-09-30 | $163.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $165.78M 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | $2.56M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $6.37M 10-K · filed 2018-02-14 | |||
| 2013-12-31 | -$424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | $123.81M derived: sum of 2 quarters · filed 2014-03-18 | $123.88M 10-K · filed 2014-03-18 | |
| 2013-09-30 | $124.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $124.30M 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $72.00K 10-Q · filed 2013-09-05 | |||
| 2012-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | $88.00K derived: sum of 2 quarters · filed 2014-03-18 | $142.00K 10-K · filed 2014-03-18 | |
| 2012-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $88.00K 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $54.00K 10-Q · filed 2013-09-05 | |||
| 2011-12-31 | $77.36M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |